BioSpace News Archive

Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe

Valeo Pharma Inc . ( CSE: VPH) (OTCQB: VPHIF) (FSE: VP2 ) (" Valeo "), a Canadian pharmaceutical company, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States . “We are pleased to have secured

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021. The presentation will be available for on-demand viewing beginning January 11, 2021 at 6:00 AM EST via the virtual conference link: htt

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision s

Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in articles in both the Wall Street Journal and BioSpace, which examined potential therapies for COVID-19 long-haulers.

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be Completed in Early 2021 -

Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using Immune Cells